Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
A multicenter, randomized, placebo-controlled, double-blind phase II ⁄ III clinical trial
Primary outcome measures:
Overall survival (OS)
The authors' conclusion was that combination therapy of elpamotide with gemcitabine was well tolerated. Despite the lack of benefit in overall survival, subgroup analysis suggested that the patients who experienced severe injection site reactions, such as ulceration and erosion, might have better survival.
Yamaue et al. 2015
…